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Abstract 8 
 9 
This article is compiled by the participants of the Expert Round Table conference “Bacteriophages as tools 10 
for therapy, prophylaxis and diagnostics” (19-21 October 2015) at the Eliava Institute of Bacteriophage, 11 
Microbiology & Virology, Tbilisi, Georgia.  The first paper from the Round Table “Silk route to the 12 
acceptance and re-implementation of bacteriophage therapy” was published in the Biotechnology Journal 13 
(2016), 11: 595-600 (DOI 10.1002/biot.201600023).  This In Focus article expands from the first one and 14 
includes recent developments reported since then by the Expert Round Table participants including the 15 
implementation of the Nagoya Protocol for the applications of bacteriophages.  16 
 17 
Introduction 18 
 19 
Antimicrobials are one of the most successful forms of therapy but their broad and often indiscriminate use 20 
resulted in a widespread antimicrobial resistance (Aminov, 2010). The annual death toll due to multidrug-21 
resistant bacterial infections is estimated at 23,000 in the US and 25,000 in Europe (CDC, 2013; EMA, 2015). 22 
Complementary strategies are urgently needed, and bacteriophage therapy offers: 23 
 24 
• Specificity, target directed removal of pathogens via narrow spectrum and do not affect beneficial 25 
commensals, 26 
• Multiplication at infection sites, thus amplifying the local antimicrobial effects,  27 
• Minimum, if any, side effects, 28 
• Resistance can be dealt by introduction of new bacteriophages, which is faster and cheaper 29 
compared to new antibiotics, 30 
• Bacteriophages are active against multidrug-resistant and biofilm-forming bacteria, 31 
• Lytic bacteriophages may limit the evolution and spread of antimicrobial resistance (Zhang and 32 
Buckling, 2012), 33 
• Bacteriophages act in synergy with antimicrobials, 34 
• Phage CRISPR-Cas systems provide a new way to target antibiotic-resistant pathogens (Yosef et 35 
al., 2015). 36 
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Bacteriophage therapy was pioneered at the Eliava Institute in Tbilisi, Georgia (Fig. 1), and the reader is 37 
referred to the excellent Historical Review article by Chanishvili and Sharp (2008) published in Microbiology 38 
Australia.   39 
 40 
 41 
 42 
Fig. 1: Bacteriophage medicine sold to patients at the Eliava Institute’s Pharmacy 43 
 44 
1. Therapeutic application of bacteriophages and resistance 45 
 46 
Large burn wounds lead to immunosuppression, making burn patients susceptible to infections. Although 47 
medical advances have resulted in increased survival of burn victims, most deaths are due to the wound 48 
sepsis or sepsis secondary to pneumonia. Animal studies showed that bacteriophages could rescue burnt mice 49 
and guinea pigs with wound infection or bacteraemia. Presently, bacteriophage therapy aficionados eagerly 50 
await the results of the “PhagoBurn” study (www.phagoburn.eu), the first trial conducted per the occidental 51 
standards of good practices. This phase I/II multicentric, randomized and single-blind clinical trial involves 15 52 
burn units in France, Switzerland and Belgium and targets burn wounds infected by Escherichia coli or 53 
Pseudomonas aeruginosa. Manufacturing the investigational products took 20 months and bacteriophage 54 
specificity issues hampered the recruitment of patients (Servick, 2016). Regardless of the clinical outcome of 55 
the trial, dedicated and realistic production requirements are urgently needed. 56 
Antagonistic bacterium-phage co-evolution is a dynamic process, where phage-resistant bacteria and 57 
infective bacteriophages are selected in turn. While emergence of bacteria resistant against challenging 58 
bacteriophages is a part of a dynamic coevolution, it could be problematic for the therapy. Thus, preventing 59 
selection of phage-resistant variants that could result in treatment failure is crucial. Interestingly, while 60 
phage-resistant P. aeruginosa can be readily selected in a test tube when challenged by the anti-P. aeruginosa 61 
cocktail used in Phagoburn, these were not observed in a rat model of P. aeruginosa-induced experimental 62 
endocarditis (Oechslin, 2016). Accordingly, two resistant variants recovered in vitro showed >70% and >40% 63 
decrease in infectivity of rats, explaining the failure to recover them from in vivo biopsies. These variants were 64 
respectively lacking lipopolysaccharide (LPS) and having the pili impaired, both structures being known as 65 
phage-receptors (Bertozzi-Silva, 2016). This study illustrated that phage-resistance can emerge at a very high 66 
cost in terms of virulence - and possibly in vivo survival - for the bacterium. This observation, which is not new 67 
(Leon, 2015), is reassuring but the clinical relevance of phage-resistance should be carefully evaluated for 68 
future clinical trials.  69  70 
2. Bacteriophages for food hygiene and safety and environmental applications 71 
 72 
Bacteriophages are used since the 1980s to control and eliminate bacterial contaminants from food 73 
surfaces, food-borne spoilage bacteria and bacteria causing gastrointestinal diseases (Garcia et al. 2008) as 74 
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well as to decontaminate raw food.  Due to their specificity, bacteriophages are attractive for sanitization of 75 
ready-to-eat foods (RTE) such as milk, vegetables and meat products (Endersen et al., 2014). In 2007, the US 76 
Department of Agriculture (USDA) approved bacteriophage products targeting Salmonella species and E. coli 77 
O157:H7. They are designed as spray sanitizers to disinfect cattle hides prior to slaughter to reduce pathogen 78 
contamination of meat (Goodridge and Abedon, 2008). In parallel, the commercial product Agriphage™ was 79 
developed to control black spot disease on tomato and pepper plants caused by Xanthamonas campestris and 80 
Pseudomonas syringae (Monk et al. 2010).  81 
Similarly, bacteriophages are also potentially useful as surface and environment decontaminants. 82 
Listeria phages (3.5 x 108 PFU/ml), for instance, were as effective as a 20-ppm solution of a quaternary 83 
ammonium compound (QAC) disinfectant for stainless steel decontamination. Interestingly, synergism 84 
between different bacteriophages and phages-QAC was reported with bacteriophages being unaffected by 85 
QAC at 50 ppm and up to 4 hours of contact time (Roy et al. 1993). 86 
 87 
3. Agricultural applications of bacteriophages  88 
 89 
Bacteriophage effects on target pathogens depend on the ecological and environmental context such as 90 
abiotic environmental factors or surrounding microbial community. For example, phage-mediated killing of 91 
pathogenic bacteria can be amplified in the presence of non-pathogenic bacteria that impose strong resource 92 
competition with the pathogen. More recently, it was shown that the presence of antimicrobial producing 93 
Bacillus amyloliquefaciens bacterium could shape the effect of bacteriophage selection on the plant pathogen 94 
Ralstonia solanacearum (Wang et al. 2017). In this case, the effect was driven by evolutionary trade-off where 95 
evolving resistance to a phage led to increased susceptibility to antimicrobials produced by B. 96 
amyloliquefaciens. Similar evolutionary trade-offs can also lead to lowered expression of multiple important 97 
R. solanacearum virulence factors and reduced virulence in tomato in vivo (Addy et al. 2012). Identifying 98 
bacteriophages that impair pathogen virulence by binding to various surface structures (flagella, pili and LPS), 99 
could be important for selecting therapeutic bacteriophages (Buttimer et al. 2017).  100 
When applied topically or orally to animals, bacteriophages will eventually become associated with 101 
the skin and wool/hair of animals. Thus, bacteriophages specific for animal pathogens could be isolated from 102 
wool (Patten et al., 1995). These bacteriophages can reduce the number of bacteria associated with 103 
'clumping', and thus represent an option for agricultural practices as opposed to antibiotics. Similarly, 104 
bacteriophages have been recovered from the skin of healthy humans (Foulongne et al., 2012), or when they 105 
were successfully incorporated into fibers used for human clothing (Mao, 2009).  106 
 107 
4. Current hurdles and regulatory status of bacteriophages  108 
 109 
Bacteriophages are not currently classified in medicinal legislation, since they are neither living nor chemical 110 
agents.  Therefore, it is complicated to regulate and perform clinical trials and commercialization (Fauconnier 111 
2017). To ensure the efficiency of phage preparations, their effectiveness and host range towards currently 112 
circulating pathogenic strains must be monitored. This might explain why the phage preparations approved in 113 
the Russian Federation and Georgia are not static but are continuously updated to target newly emerging 114 
pathogenic strains (Kutter et al. 2010). Legislation to allow these updates is necessary to circumvent repeated 115 
registration procedures. 116 
On July 5 2016, the Belgian Minister of Social Affairs and Public Health has formally acknowledged that it 117 
is difficult to define the status of therapeutic phage preparations: should they be considered as industrially-118 
prepared medicinal products (subjected to constraints related to marketing authorization) or as magistral 119 
preparations (prepared in pharmacies’ officina) (Commission de la santé publique, de l'environnement et du 120 
renouveau de la société, 2016). Magistral preparations (compounded prescription drug products in the US) 121 
are made by a pharmacist from the constituent ingredients to meet specific patient needs. On October 26th, 122 
2016, it was formally agreed that natural bacteriophages and their products, which are not fully compliant 123 
with the European Directive requirements for medicinal products for human use and for which there is no 124 
monograph in an official pharmacopoeia, can be processed by a pharmacist as raw materials (active 125 
ingredients) in magistral preparations, providing compliance to several logical provisions.   126 
 127 
 128 
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5. Bacteriophage application in the Access and Benefit Sharing (ABS) context: The Nagoya Protocol  131 
 132 
To combat antibiotic resistances, there is urgent need to build up large phage collections against the 133 
pathogens like ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 134 
baumannii, P. aeruginosa and Enterobacteriaceae). However, culture collections holding and offering quality-135 
checked authenticated bacteriophages in the sense of phage banks are confronted with two constraints. First, 136 
there are no requirements for authors by journals to deposit bacteriophages with public repositories before 137 
publishing, which differs from agreed procedures for their bacterial hosts (Murray, 1996). The second issue 138 
that should be considered is the current development of rules for legal handling of bioresources that of 139 
course includes the bacteriophages.  On October 12th, 2014, the Nagoya Protocol https://www.cbd.int/abs/ 140 
has entered force in several countries that ratified the Convention on Biological Diversity (CBD) 141 
https://www.cbd.int/.  These laws deal with sampling, the accession and distribution of all genetic resources 142 
including microorganisms regarding the ABS. One of the reasons of the ratification of the protocol is 143 
protecting biodiversity under national sovereignty to prevent “biopiracy” and to restrict access. All 144 
microbiologists who are sampling or distributing bioresources must be aware of these restrictions and should 145 
refer to their respective national regulations.  National regulations might differ in each country and failure to 146 
comply with might result in legal consequences. For further information please see the DSMZ website at 147 
https://www.dsmz.de/deposit/nagoya-protocol.html. 148 
 149 
6. Conclusions and Future Perspectives 150 
 151 
As already stated by Skurnik and Strauch (2006) a decade ago, the therapeutic use of 152 
bacteriophages, possibly combined with antibiotics, is a promising therapy option. Safe and 153 
controlled use of bacteriophage therapy will however, require as detailed information as possible on the 154 
properties and behaviour of specific phage-bacterium systems, in vitro and especially in vivo. Susceptibility of 155 
bacterial pathogens in vivo to bacteriophages is still not completely understood and requires dedicated (pre-156 
)clinical research on more phage-bacterium systems. The requirements for quality and safety in 157 
bacteriophage production and application have been defined and communicated (Pirnay et al., 2015; 158 
Verbeken et al., 2014, Fauconnier, 2017).   159 
Natural resources will naturally be utilized further to isolate many more bacteriophages to build-up 160 
large phage collections to fight the antibiotic crisis.  These efforts will then be translated into cooperation 161 
across borders and continents which will be regulated by The Nagoya Protocol to some extent. Therefore, 162 
facilitative regulations governing therapeutic use of bacteriophages should be implemented to counter 163 
antibiotic resistance on a global scale.  Bacteriophage application obviously have significant potential to 164 
bridge human and veterinary medicine and bring effective solutions to antibiotic resistant problem as pointed 165 
out in this article. 166 
 167 
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